Article

Single-center retrospective clinical evaluation of venetoclax combined with HMAs and half-dose CAG in the treatment of unfit or refractory/relapsed AML

2022-07-01

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold> The prognosis of unfit or relapsed/refractory (R/R) AML patients remains poor. Venetoclax has been proved to have anti-leukemia stem cell activity. However, there is little published information on the efficacy and safety of VEN combined with both demethylated drugs and half-dose chemotherapy in the treatment of unfit or R/R AML patients.<bold>Methods</bold> In this...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ec74b45e-00bb-5945-b3d4-e10af382f0d9
DOI: 10.21203/rs.3.rs-1793347/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Single-center retrospective clinical evaluation of venetoclax combined with HMAs and half-dose CAG in the treatment of unfit or refractory/relapsed AMLDOI 10.21203/rs.3.rs-1793347/v1Read

The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaSemantic proximity Read

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read

Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.Semantic proximity Read

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemiaSemantic proximity Read

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensSemantic proximity Read

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity Read

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read

Venetoclax and hypomethylating agents in FLT3 ‐mutated acute myeloid leukemiaSemantic proximity Read

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.Semantic proximity Read

Advancements and Challenges in the Treatment of AML.Semantic proximity Read